Newton Biocapital

Newton Biocapital is a Brussels-based venture capital firm dedicated to investing in the life sciences sector, with a specialized focus on chronic diseases. Established with a strong European footprint, the firm primarily targets innovative biotech and medtech companies in Belgium, France, and extends its reach to Japan. Their investment thesis centers on addressing significant unmet medical needs across therapeutic areas such as oncology, immunology, and rare diseases, aiming to support the development of groundbreaking therapies from early stages.

The firm's investment strategy is geared towards early-stage opportunities, typically engaging with companies from the pre-clinical phase up to clinical stage 2. Newton Biocapital seeks to identify promising technologies and platforms that have the potential for significant clinical and commercial impact. Their initial investment per company generally ranges from €2 million to €7 million. Beyond the initial capital injection, Newton Biocapital is committed to providing ongoing support, often participating in follow-on rounds, which can bring their total investment per portfolio company to as much as €10 million to €15 million. This approach underscores their long-term partnership philosophy with their portfolio companies.

Newton Biocapital successfully closed its first fund, Newton Biocapital I, at €105 million in 2018, demonstrating investor confidence in their specialized approach. Building on this success, the firm launched Newton Biocapital II in 2023, with an ambitious target of raising €150 million to €200 million. This expansion reflects their continued commitment to fostering innovation in the life sciences and their growing influence within the European and Japanese biotech ecosystems. The firm's strategic partnerships and deep industry expertise position it as a significant player in advancing novel treatments for chronic conditions.